Senti Biosciences, Inc. (NASDAQ:SNTI) Short Interest Down 38.7% in December

Senti Biosciences, Inc. (NASDAQ:SNTI) saw a large drop in short interest during the month of December. As of December 31st, there was short interest totaling 1,019,881 shares, a drop of 38.7% from the December 15th total of 1,663,760 shares. Based on an average daily volume of 511,420 shares, the short-interest ratio is presently 2.0 days. Currently, 4.0% of the company’s shares are short sold. Currently, 4.0% of the company’s shares are short sold. Based on an average daily volume of 511,420 shares, the short-interest ratio is presently 2.0 days.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Chardan Capital lifted their price target on Senti Biosciences from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Leerink Partnrs upgraded shares of Senti Biosciences to a “strong-buy” rating in a report on Friday, November 21st. Wall Street Zen raised shares of Senti Biosciences to a “sell” rating in a research note on Saturday, December 13th. HC Wainwright initiated coverage on shares of Senti Biosciences in a report on Tuesday, October 14th. They set a “buy” rating and a $12.00 price target for the company. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Senti Biosciences in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $9.00.

Institutional Investors Weigh In On Senti Biosciences

Hedge funds have recently made changes to their positions in the company. Citadel Advisors LLC bought a new stake in Senti Biosciences in the 3rd quarter worth about $117,000. Armistice Capital LLC bought a new position in Senti Biosciences during the 2nd quarter valued at about $1,883,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Senti Biosciences by 395.6% during the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after acquiring an additional 117,588 shares during the last quarter. 25.70% of the stock is currently owned by institutional investors.

Senti Biosciences Stock Performance

SNTI stock traded down $0.03 on Friday, reaching $1.03. The company’s stock had a trading volume of 177,179 shares, compared to its average volume of 325,040. The business has a fifty day simple moving average of $1.50 and a two-hundred day simple moving average of $1.67. Senti Biosciences has a 12-month low of $1.03 and a 12-month high of $5.10.

Senti Biosciences (NASDAQ:SNTI) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.10). As a group, research analysts expect that Senti Biosciences will post -14.54 earnings per share for the current year.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.